Indications

Chronic Obstructive Pulmonary Disease (COPD) (see Chronic Obstructive Pulmonary Disease)

Clinical Efficacy

• O-COPD Randomized Trial of Positive Expiratory Pressure Therapy in Chronic Obstructive Pulmonary Disease (Thorax, 2022) [MEDLINE]
  • n = 122 (61/61 Oscillatory Positive Expiratory Pressure Therapy/Control) were recruited (103 completed the study: 55/48 Oscillatory Positive Expiratory Pressure Therapy/Control)
    • 40% female
    • 17% smokers
    • FEV1 38 (25-56)% Predicted
    • Age 62±10 y/o
  • Use of Oscillatory Positive Expiratory Pressure was Associated with Improvement in Leicester Cough Questionnaire, as Compared to Control; Median 1.03 (95% CI: 0.71 to 2.10; p = 0.03), Functional Assessment of Chronic Illness Therapy Score 4.68 (95% CI: 1.34 to 8.02; p<0.001), and EuroQol-5 Dimensions Score 4.00 (95% CI: 0.49 to 19.75; p=0.04)
  • There was Also an Improvement in Cough Frequency -60 (-43 to -95) Coughs/24 hours (p<0.001), But No Statistically Significant Effect on Sleep Disturbance was Identified
  • Regular Use of an Acapella Device Improves Symptoms and Quality of life in COPD Patients Who Produce Sputum Daily or Most Days

---

Technique

Brands

• Acapella
• Aerobika
• Bottle PEP
• PARI O-PEP
• Flutter
• Turboforte®

Physiology

• clearance of excess secretions from the lungs
• reducing gas trapping and improving ventilation of the lungs

---

Adverse Effects

XXXX

• xxxx

---

References

• Oscillatory positive expiratory pressure therapy in COPD (O-COPD): a randomised controlled trial. Thorax. 2022 Aug 10;thoraxjnl-2022-219077. doi: 10.1136/thorax-2022-219077 [MEDLINE]